Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.

MLA

Wang, Dian, et al. “Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.” JAMA Oncology, vol. 9, no. 5, May 2023, pp. 646–55. EBSCOhost, https://doi.org/10.1001/jamaoncol.2023.0042.

APA

Wang, D., Harris, J., Kraybill, W. G., Eisenberg, B., Kirsch, D. G., Ettinger, D. S., Kane, J. M., 3rd, Barry, P. N., Naghavi, A., Freeman, C. R., Chen, Y.-L., Hitchcock, Y. J., Bedi, M., Salerno, K. E., Severin, D., Godette, K. D., Larrier, N. A., Curran, W. J., Jr, Torres-Saavedra, P. A., & Lucas, D. R. (2023). Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials. JAMA Oncology, 9(5), 646–655. https://doi.org/10.1001/jamaoncol.2023.0042

Chicago

Wang, Dian, Jonathan Harris, William G Kraybill, Burt Eisenberg, David G Kirsch, David S Ettinger, John M Kane 3rd, et al. 2023. “Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.” JAMA Oncology 9 (5): 646–55. doi:10.1001/jamaoncol.2023.0042.